In vitro and in vivo data presented showed that etarfolatide binds with high affinity (Kd around 3 nM) to the folate receptor, independent of cell type. Furthermore, the binding specificity of etarfolatide to cells or its accumulation within tumors depends on folate receptor expression. The pharmacologic properties of both etarfolatide and vintafolide were investigated in human and murine cell lines as well as in xenograft (transplants into other species) models."These data indicate that we can predict with our companion diagnostic etarfolatide which tissues will accumulate, and potentially respond to, folate-containing therapeutics like the SMDC vintafolide, which is a much needed personalized approach," said Christopher Leamon, Ph.D., vice president of research and development for Endocyte and presenter of the study.
Endocyte's Investigational Diagnostic Imaging Agent Etarfolatide Identifies Ovarian Cancer And Non-Small Cell Lung Cancer Patients Most Likely To Benefit From Folate Receptor-Targeted Treatment, New Analysis Shows
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts